The year 2022 marked a turning point for our institute with the creation of its new technology department (WEL-T) and a growing societal and economic impact in health (WELBIO).

Congratulations to Philippe Denoël, Head of Vaccines External R&D at GSK, succeeding to Jean Stéphenne to the role of President of the Governing Board of the WEL Research Institute.  

Benoit Van den Eynde's team discovered a new fundamental mechanism, using molecules previously used to treat hypertension, which could help the immune system to fight cancer cells more effectively.

From bench to bedside: How an understanding of the mechanisms of vascular development in Miikka Vikkula's lab led to the prenatal treatment of a foetus suffering from a lymphatic malformation by Dr Laurence Boon's team.

For 20 years, Stefan Constantinescu's team has been trying to establish the molecular basis of certain blood cancers (myeloproliferative neoplasms) with several discoveries to their credit.

Laure Bindels and her team showed that altered hepatic AHR receptor signalling could promote liver disorders in cancer cachexia, a syndrome that induces weight loss, muscle wasting and immune deficiency.

Amandine Everard's team demonstrated a causal link between the intestinal microbiota, and more precisely a phenolic metabolite produced by it, and compulsive eating behaviours.

Ana Beloqui and her team developed an oral formulation, based on lipid nanoparticles, of drugs usually administered by subcutaneous injection in the treatment of non-alcoholic fatty liver disease.

Cédric Blanpain's team discovered that RHOJ allows cancer cells with EMT to resist chemotherapy.

Thomas Marichal and his team have discovered that blood monocytes, previously considered to be differentiated cells, are in fact capable of proliferating to replace tissue macrophages.

Jean-François Collet and colleagues discovered that the chaperone GroEL works with CnoX, a chaperedoxin that controls the redox quality of GroEL substrates.

Decio L. Eizirik is the recipient of the prestigious George Eisenbarth Memorial Lecture that will be delivered at the 15th annual Network for Pancreatic Organ Donors with Diabetes (nPOD) meeting in Florida, USA.